Replies to post #26944 on Biotech Values

[iOwnSomeBio]

Lovenox has always had these competitors (fondiparinux, dalteparin, etc.). It continues to hold the majority of the market - $3 bil. These competitors are not new. MNTA is hoping to get a split of the $3 bil that lovenox now holds.